LY2510924 + Carboplatin + Etoposide
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive Stage Small Cell Lung Carcinoma
Conditions
Extensive Stage Small Cell Lung Carcinoma
Trial Timeline
Sep 1, 2011 → Aug 1, 2016
NCT ID
NCT01439568About LY2510924 + Carboplatin + Etoposide
LY2510924 + Carboplatin + Etoposide is a phase 2 stage product being developed by Eli Lilly for Extensive Stage Small Cell Lung Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01439568. Target conditions include Extensive Stage Small Cell Lung Carcinoma.
What happened to similar drugs?
0 of 11 similar drugs in Extensive Stage Small Cell Lung Carcinoma were approved
Approved (0) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01439568 | Phase 2 | Completed |
Competing Products
20 competing products in Extensive Stage Small Cell Lung Carcinoma